





**FAX Completed Form To** 1.833.404.2392 Prescriber Help Desk 1.833.587.2012

Online covermymeds.com/main/ prior-authorization-forms/

## **Request for Prior Authorization TESTOSTERONE PRODUCTS**

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax NI	DC

Prior authorization is required for testosterone products. Payment will be considered with documentation of a specific testicular or hypothalamic/pituitary disease (primary hypogonadism or hypogonadotropic hypogonadism) that results in classic hypogonadism. Requests for FDA approved indications other than hypogonadism will not be subject to prior authorization criteria with adequate documentation of diagnosis. Payment for non-preferred testosterone products will be authorized only for cases in which there is documentation of previous trials and therapy failures with two preferred agents. Requests for erectile dysfunction, infertility, and age-related hypogonadism will not be considered. Payment will be considered under the following conditions:

- 1) Patient is male and 18 years of age or older (or 12 years of age and older for testosterone cypionate); and
- 2) Patient has two (2) morning pre-treatment testosterone levels below the lower limit of the normal testosterone reference range of the individual laboratory used (attach results); and
- 3) Patient has primary hypogonadism or hypogonadotropic hypogonadism (further defined below)
  - Primary hypogonadism (congenital or acquired) caused by testicular failure due to one of the following: cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, toxic damage from alcohol or heavy metals
  - Hypogonadotropic hypogonadism: idiopathic gonadotropin or luteinizing hormone-releasing (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation
- Patient does not have:
  - Breast or prostate cancer
  - Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL
  - Hematocrit > 50%
  - Untreated severe obstructive sleep apnea
  - Severe lower urinary tract symptoms
  - Uncontrolled or poorly controlled heart failure

If criteria for coverage are met, initial authorizations will be given for 3 months. Requests for continuation of therapy will require the following:

- An updated testosterone level (attach result); and
- Documentation the patient has not experienced a hematocrit > 54% or an increase in PSA > 1.4ng/mL in the past 12 months.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Rev. 10/22 Page 1 of 2







## FAX Completed Form To 1.833.404.2392 Prescriber Help Desk

Online covermymeds.com/main/

prior-authorization-forms/

1.833.587.2012

## Request for Prior Authorization TESTOSTERONE PRODUCTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Androderm Androgel Jatenzo Testim Tile Testosterone Cypionate Aveed Methitest Testosterone Gel 1.62% Xy Testosterone Enanthate Depo-Testosterone Methyltestosterone Testosterone Gel Pump Vo Testosterone Gel 1% Packets Fortesta Natesto Testosterone Topical Solution	ando osted
☐ Testosterone Enanthate ☐ Depo-Testosterone ☐ Methyltestosterone ☐ Testosterone Gel Pump ☐ Vo	osted
☐ Testosterone Gel 1% Packets ☐ Fortesta ☐ Natesto ☐ Testosterone Topical Solution	gelxo
Strength Dosage Instructions Quantity Days Supply	
Complete for diagnosis of hypogonadism:	
<ul> <li>□ Primary Hypogonadism (congenital or acquired) caused by testicular failure due to one of the following:</li> <li>□ Cryptorchidism □ Bilateral torsion □ Orchitis □ Vanishing testes syndrome □ Orchiectomy</li> <li>□ Klinefelter's syndrome □ Chemotherapy □ Toxic damage from alcohol or heavy metals</li> <li>□ Other: □</li> </ul>	
<ul> <li>☐ Hypogonadotropic Hypogonadism:</li> <li>☐ Idiopathic gonadotropin or luteinizing hormone-releasing (LHRH) deficiency</li> <li>☐ Pituitary-hypothalamic injury from tumors, trauma, or radiation</li> </ul>	
Please indicate setting in which medication is to be administered:  List & attach results of two (2) morning pre-treatment testosterone levels below the lower limit of the normal testosteror reference range of the individual laboratory used:	е
Level 1: Date: Level 2: Date:	
Does patient have any of the following:	
Breast or prostate cancer:	
Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL:	
Hematocrit > 50%: ☐ Yes ☐ No	
Untreated severe obstructive sleep apnea:	
Severe lower urinary tract symptoms:	
I be controlled an acceptance to the data of failures.	
Uncontrolled or poorly controlled heart failure:	
Uncontrolled or poorly controlled heart failure:	
Renewal Requests:  List & attach updated testosterone level: Level: Date:	
Renewal Requests:  List & attach updated testosterone level: Level: Date:  Has patient experienced the following in the past 12 months:	
Renewal Requests:  List & attach updated testosterone level: Level: Date:  Has patient experienced the following in the past 12 months:	
Renewal Requests:  List & attach updated testosterone level: Level: Date:  Has patient experienced the following in the past 12 months:  Hematocrit > 54%:	
Renewal Requests:  List & attach updated testosterone level: Level:	

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

Rev. 10/22 Page 2 of 2